Drug Trial Radar · NCT06030375
Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567
Last checked: Nov 19, 2026Latest source record: Sep 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Feb 17, 2020
Primary completion
Apr 27, 2020
Study completion Apr 27, 2020
Sponsor
- Lead sponsor
- Novakand Pharma ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study was planned to consist of 24 healthy subjects in 3 dosing cohorts receiving a continuous i.v. infusion of KAND567 or placebo for 6 h (6 subjects on active and 2 subjects on placebo per cohort), with the option of two additional cohorts of the same size and group composition.
Conditions
- Healthy
Interventions
KAND567Drug
Continuous intravenous infusion for 6 hours
PlaceboOther
Continuous intravenous infusion for 6 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability after continuous infusion of KAND567, as measured by adverse events (AEs)Time frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
- Safety and tolerability after continuous infusion of KAND567, as measured by vital signsTime frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
- Safety and tolerability after continuous infusion of KAND567, as measured by ECGTime frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
- Safety and tolerability after continuous infusion of KAND567, as measured by lab safety testsTime frame: From the first IMP administration (Day 1) until the last follow-up visit (Day 30)
- Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by CssTime frame: From the first IMP administration (Day 1) until Day 2
- Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by AUCTime frame: From the first IMP administration (Day 1) until Day 2
- Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by t1/2zTime frame: From the first IMP administration (Day 1) until Day 2
- Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by VssTime frame: From the first IMP administration (Day 1) until Day 2
- Pharmacokinetics (PK) after continuous infusion of KAND567, as measured by CLTime frame: From the first IMP administration (Day 1) until Day 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Services Turku (CRST)
Turku, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.